PriceTargets.com logo

Obsidian Therapeutics - OBX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $42.50
  • Forecasted Upside: 139.44%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$17.75 As of 09/18/2026 05:00 PM ET
▲ +0.25 (1.43%)

This chart shows the closing price for OBX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Obsidian Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OBX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OBX

Analyst Price Target is $42.50
▲ +139.44% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Obsidian Therapeutics in the last 3 months. The average price target is $42.50, with a high forecast of $43.00 and a low forecast of $42.00. The average price target represents a 139.44% upside from the last price of $17.75.

This chart shows the closing price for OBX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 6 contributing investment analysts is to moderate buy stock in Obsidian Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2026
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2026
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/20/2026
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/19/2026

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/9/2026William BlairInitiated CoverageOutperform
9/2/2026Weiss RatingsInitiated CoverageSell (D-)
8/18/2026Lifesci CapitalInitiated CoverageOutperform$43.00
8/6/2026TD CowenInitiated CoverageBuy
8/6/2026Zacks ResearchUpgradeHold
8/5/2026Piper SandlerInitiated CoverageOverweight$42.00
(Data available from 9/20/2021 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/22/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/23/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/22/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/22/2026
  • 0 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2026

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.

Obsidian Therapeutics

Obsidian Therapeutics Inc. is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian Therapeutics Inc. is based in CAMBRIDGE, Mass.
Read More

Today's Range

Now: $17.75
Low: $17.36
High: $18.16

50 Day Range

MA: N/A

52 Week Range

Now: $17.75
Low: $14.57
High: $49.97

Volume

3,974,350 shs

Average Volume

375,483 shs

Market Capitalization

$1.10 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Obsidian Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Obsidian Therapeutics in the last year: Lifesci Capital, Piper Sandler, TD Cowen, Wall Street Zen, Weiss Ratings, William Blair, and Zacks Research.
View the latest analyst ratings for OBX.

What is the current price target for Obsidian Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Obsidian Therapeutics in the last year. Their average twelve-month price target is $42.50, suggesting a possible upside of 139.4%. Lifesci Capital has the highest price target set, predicting OBX will reach $43.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $42.00 for Obsidian Therapeutics in the next year.
View the latest price targets for OBX.

What is the current consensus analyst rating for Obsidian Therapeutics?

Obsidian Therapeutics currently has 1 sell rating, 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for OBX.

How do I contact Obsidian Therapeutics' investor relations team?

Obsidian Therapeutics' physical mailing address is 1030 Massachusetts Avenue, Cambridge, MA, 02138. The company's listed phone number is 781-806-6245 and its investor relations email address is [email protected]. The official website for Obsidian Therapeutics is www.obsidiantx.com. Learn More about contacing Obsidian Therapeutics investor relations.